-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Shijiazhuang Sihua Pharmaceutical Group’s Calcium Leucovorin for Injection Approved
Category:
发布时间：2026-03-09
【概要描述】
Spring is the best time of year, and now is the perfect moment to forge ahead. On March 6, Shijiazhuang Sihua Pharmaceutical Group’s Class 3 chemical drug—calcium leucovorin for injection (25 mg, calculated on the basis of C20H23N7O7)—received production registration approval from the National Medical Products Administration and is deemed to have passed the consistency evaluation. This marks the group’s 10th newly approved product so far this year.
Spring is the best time of year, and now is the perfect moment to forge ahead. On March 6, Shijiazhuang Sihua Pharmaceutical Group’s Class 3 chemical drug—calcium leucovorin for injection (25 mg, calculated on the basis of C20H23N7O7)—received production registration approval from the National Medical Products Administration and is deemed to have passed the consistency evaluation. This marks the group’s 10th newly approved product so far this year.
According to available information, calcium leucovorin for injection is used in combination with 5-fluorouracil for the treatment of gastric cancer and colorectal cancer.
In recent years, guided by innovation-driven development and the pursuit of high-quality growth, the Group has continuously enhanced its innovation capabilities, consistently met market demands, and effectively accelerated the emergence of innovative outcomes. To date, 170 product varieties comprising 222 specifications have either passed or been deemed to have passed the consistency evaluation, providing strong momentum for the Company to capture untapped market opportunities and unlock new growth prospects.
Looking ahead, the Group will continue to leverage “a combination of generic and innovative drug development” as its driving force, accelerating the R&D and commercialization of more innovative medicines and high-end complex formulations, thereby expanding access for both the market and patients and contributing to the Healthy China initiative.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091